InnoCare's Soficitinib Hits Primary Endpoint in Vitiligo Trial — InnoCare Pharma Limited

Event summary

Phase II trial of TYK2 inhibitor soficitinib (ICP-332) met primary endpoint in non-segmental vitiligo patients.
80 mg and 120 mg doses showed 38.8% and 41.2% improvement in F-VASI vs. 2.2% for placebo at Week 24 (P<0.0001).
Soficitinib demonstrated favorable safety profile with no new signals identified.
Results to be presented at upcoming scientific congresses and academic journals.

The big picture

InnoCare's positive Phase II results for soficitinib reinforce the growing interest in TYK2 inhibitors as a therapeutic class for dermatological conditions. The data positions InnoCare competitively within the autoimmune space, where oral treatments with favorable safety profiles are increasingly sought after. Success here could expand InnoCare's footprint beyond oncology into high-value dermatology markets.

What we're watching

Regulatory Pathway: The pace at which InnoCare advances soficitinib into Phase III trials and potential regulatory filings.
Market Positioning: How these results position soficitinib against existing and emerging TYK2 inhibitors in the dermatology market.
Pipeline Strategy: Whether InnoCare can leverage this success to accelerate development of other autoimmune indications in its pipeline.